Wells Fargo & Company Decibel Therapeutics, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$2.41 - $4.81 $9 - $19	4 Added 4.44%	94 $0
Q1 2023 May 12, 2023	BUY	$2.08 - $4.79 $4 - $9	2 Added 2.27%	90 $0
Q4 2022 Feb 13, 2023	BUY	$1.86 - $3.54 $3 - $7	2 Added 2.33%	88 $0
Q3 2022 Nov 14, 2022	BUY	$3.82 - $5.61 $145 - $213	38 Added 79.17%	86 $0
Q2 2022 Aug 12, 2022	BUY	$1.85 - $4.21 $88 - $202	48 New	48 $0
Q4 2021 Feb 14, 2022	SELL	$4.57 - $8.58 $201 - $377	-44 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.6 - $9.04 $13 - $18	-2 Reduced 4.35%	44 $0
Q2 2021 Aug 16, 2021	SELL	$6.39 - $11.51 $13,949 - $25,126	-2,183 Reduced 97.94%	46 $0
Q1 2021 May 13, 2021	BUY	$10.56 - $19.9 $23,538 - $44,357	2,229 New	2,229 $25,000

Ticker DBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,964,500
Description
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.